Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
12,364
Total Claims
$1.1M
Drug Cost
545
Beneficiaries
$1,950
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+38%
Cost per patient vs peers
$1,950 vs $1,411 avg
+12%
Brand preference vs peers
11.9% vs 10.6% avg
Brand vs Generic
Brand: 1,455 claims · $832K
Generic: 10,768 claims · $221K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Insulin Glargine,hum.Rec.Anlog | 147 | $130K |
| Rivaroxaban | 84 | $109K |
| Apixaban | 90 | $100K |
| Sitagliptin Phosphate | 73 | $77K |
| Linagliptin | 35 | $42K |
| Insulin Regular, Human | 58 | $34K |
| Insulin Nph Hum/Reg Insulin Hm | 40 | $31K |
| Omega-3 Acid Ethyl Esters | 222 | $27K |
| Sacubitril/Valsartan | 13 | $19K |
| Dulaglutide | 15 | $16K |
| Ticagrelor | 12 | $16K |
| Gabapentin | 731 | $14K |
| Losartan Potassium | 618 | $12K |
| Insulin Glargine-Yfgn | 37 | $12K |
| Levothyroxine Sodium | 504 | $12K |
Prescribing Profile
Patient Profile
70
Avg Age
59%
Female
1.83
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data